Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Collection
Nature Biotechnology's academic spinouts 2023
Nature Biotechnology’s annual survey highlights academic startups that are, among other things, correcting misfolded or disordered proteins, creating second generation GPCR agonists, building a new gene delivery platform, and mining cancer genomes for novel targets.
Some 700 approved therapies in the United States — roughly a third of all drugs on the market — target G-protein-coupled receptors (GPCRs). Now advances in high-throughput and structure-based screening are sparking a second golden age of GPCR-based drug discovery.